Financials AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. 11:35:12 2024-02-23 am EST 5-day change 1st Jan Change
10,220 GBX +1.83% Intraday chart for AstraZeneca PLC +1.25% -3.58%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 132,331 131,461 181,878 210,243 209,128 200,780 - -
Enterprise Value (EV) 1 144,340 143,328 206,261 233,166 231,638 218,783 212,854 204,534
P/E ratio 97.9 x 41 x 1,468 x 64.3 x 35.4 x 22.6 x 19.4 x 17 x
Yield 2.78% 2.8% 2.44% 2.14% 2.15% 2.41% 2.52% 2.54%
Capitalization / Revenue 5.43 x 4.94 x 4.86 x 4.74 x 4.57 x 3.94 x 3.68 x 3.5 x
EV / Revenue 5.92 x 5.38 x 5.51 x 5.26 x 5.06 x 4.3 x 3.9 x 3.57 x
EV / EBITDA 21.6 x 17.2 x 27.2 x 25.2 x 17.1 x 12.2 x 10.6 x 10 x
EV / FCF 72.5 x 37.3 x 42.3 x 26.7 x 25.8 x 24.6 x 18.6 x 15.7 x
FCF Yield 1.38% 2.68% 2.36% 3.74% 3.88% 4.06% 5.37% 6.38%
Price to Book 10 x 8.41 x 4.24 x 5.67 x 5.38 x 4.64 x 4.02 x 3.8 x
Nbr of stocks (in thousands) 1,311,913 1,312,660 1,549,159 1,549,528 1,549,926 1,550,189 - -
Reference price 2 100.9 100.1 117.4 135.7 134.9 129.5 129.5 129.5
Announcement Date 2/14/20 2/11/21 2/10/22 2/9/23 2/8/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 24,384 26,617 37,417 44,351 45,811 50,921 54,600 57,310
EBITDA 1 6,686 8,311 7,586 9,237 13,580 17,907 19,997 20,368
EBIT 1 6,436 7,340 9,928 13,350 14,534 16,951 19,113 20,064
Operating Margin 26.39% 27.58% 26.53% 30.1% 31.73% 33.29% 35% 35.01%
Earnings before Tax (EBT) 1 1,548 3,916 -265 2,501 6,899 10,351 12,551 13,700
Net income 1 1,335 3,196 112 3,288 5,961 8,607 10,057 11,116
Net margin 5.47% 12.01% 0.3% 7.41% 13.01% 16.9% 18.42% 19.4%
EPS 2 1.030 2.440 0.0800 2.110 3.810 5.719 6.668 7.623
Free Cash Flow 1 1,990 3,838 4,872 8,717 8,984 8,876 11,424 13,056
FCF margin 8.16% 14.42% 13.02% 19.65% 19.61% 17.43% 20.92% 22.78%
FCF Conversion (EBITDA) 29.76% 46.18% 64.22% 94.37% 66.16% 49.57% 57.13% 64.1%
FCF Conversion (Net income) 149.06% 120.09% 4,350% 265.12% 150.71% 103.12% 113.59% 117.45%
Dividend per Share 2 2.800 2.800 2.870 2.900 2.900 3.120 3.269 3.292
Announcement Date 2/14/20 2/11/21 2/10/22 2/9/23 2/8/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 9,866 12,011 11,390 10,771 10,982 11,207 10,879 11,416 11,492 12,024 12,107 12,481 12,868 13,636 12,830
EBITDA 1 1,114 1,900 2,187 1,896 2,579 2,574 - 3,732 - - 4,321 4,554 4,675 5,045 -
EBIT 1 2,281 3,318 3,961 3,365 3,413 2,610 3,946 4,291 3,545 2,752 4,524 3,978 4,251 4,033 -
Operating Margin 23.12% 27.62% 34.78% 31.24% 31.08% 23.29% 36.27% 37.59% 30.85% 22.89% 37.37% 31.87% 33.04% 29.57% -
Earnings before Tax (EBT) 1 -2,001 -636 553 247 922 778 2,262 2,088 1,652 897 2,575 2,666 3,045 2,561 -
Net income 1 -1,652 -347 386 360 1,640 901 1,803 1,818 1,378 959 2,415 2,186 2,363 2,267 -
Net margin -16.74% -2.89% 3.39% 3.34% 14.93% 8.04% 16.57% 15.93% 11.99% 7.98% 19.95% 17.51% 18.37% 16.63% -
EPS 2 -1.100 -0.2200 0.2500 0.2300 1.050 0.5800 1.160 1.170 0.8900 0.6200 1.548 1.398 1.514 1.455 -
Dividend per Share 2 - 1.970 - 0.9300 - 1.970 - 0.9300 - 1.970 0.8000 0.8900 0.8000 1.435 0.8500
Announcement Date 11/12/21 2/10/22 4/29/22 7/29/22 11/10/22 2/9/23 4/27/23 7/28/23 11/9/23 2/8/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 12,009 11,867 24,383 22,923 22,510 18,003 12,074 3,755
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.796 x 1.428 x 3.214 x 2.482 x 1.658 x 1.005 x 0.6038 x 0.1843 x
Free Cash Flow 1 1,990 3,838 4,872 8,717 8,984 8,876 11,424 13,056
ROE (net income / shareholders' equity) 35.6% 36.7% 27.5% 27.2% 29.8% 29.1% 30.7% 28.2%
ROA (Net income/ Total Assets) 2.19% 4.99% 8.77% 3.26% 11.5% 10% 10.9% 11.3%
Assets 1 61,015 64,053 1,277 100,924 51,935 86,104 92,481 98,126
Book Value Per Share 2 10.10 11.90 27.70 23.90 25.10 27.90 32.20 34.10
Cash Flow per Share 2 2.280 3.660 4.180 6.290 6.620 9.230 10.40 8.040
Capex 1 979 961 1,091 1,091 1,361 1,753 1,821 2,006
Capex / Sales 4.01% 3.61% 2.92% 2.46% 2.97% 3.44% 3.34% 3.5%
Announcement Date 2/14/20 2/11/21 2/10/22 2/9/23 2/8/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
129.5 USD
Average target price
161.8 USD
Spread / Average Target
+24.89%
Consensus
1st Jan change Capi.
-3.58% 201 B $
+32.01% 693 B $
+21.62% 550 B $
+3.25% 390 B $
+18.74% 328 B $
+14.92% 315 B $
+7.97% 213 B $
-4.95% 212 B $
-3.58% 157 B $
+0.42% 155 B $
Other Pharmaceuticals
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW